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1. 
ANT-ADHESIVE BARRIER MEMBRANE 
USING ALGNATE AND HYALURONCACD 
FOR BOMEDICAL APPLICATIONS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. patent applica 
tion No. 61/391,299, filed Oct. 8, 2010. 
STATEMENT OF FEDERALLY FUNDED 
RESEARCH 
This invention was made with U.S. Government support 
under Contract Nos. BES-021744 and BES-0500969 
awarded by the National Science Foundation (NSF). The 
government has certain rights in this invention. 
TECHNICAL FIELD OF THE INVENTION 
The present invention relates in general to the field of 
biopolymers, and more particularly to a non-toxic, anti-ad 
hesion hydrogel barrier comprising biocompatible polysac 
charides. 
INCORPORATION-BY-REFERENCE OF 
MATERIALS FILED ON COMPACT DISC 
None. 
REFERENCE TO ASEQUENCE LISTING 
None. 
BACKGROUND OF THE INVENTION 
Without limiting the scope of the invention, its background 
is described in connection with the porous biopolymer hydro 
gels and methods of preparing the same. 
WIPO Patent Publication No. WO 2009/108760 A8 
(Zawko and Schmidt, 2009) discloses a hydrogel and a 
method of makingaporous hydrogel by preparing an aqueous 
mixture of an uncrosslinked polymer and a crystallizable 
molecule; casting the mixture into a vessel; allowing the cast 
mixture to dry to form an amorphous hydrogel film; seeding 
the cast mixture with a seed crystal of the crystallizable mol 
ecule; growing the crystallizable molecule into a crystal 
structure within the uncrosslinked polymer, crosslinking the 
polymer around the crystal structure under conditions in 
which the crystal structure within the crosslinked polymer is 
maintained; and dissolving the crystals within the crosslinked 
polymer to form the porous hydrogel. 
U.S. Patent Publication No. 20100209509 (Kao et al., 
2010) discloses hydrogels wherein a polymer matrix is modi 
fied to contain a bifunctional poly(alkylene glycol) molecule 
covalently bonded to the polymer matrix. The hydrogels can 
be cross-linked using, for example, glutaraldehyde. The 
hydrogels may also be crosslinked via an interpenetrating 
network of a photopolymerizable acrylates. The hydrogels 
may also be modified to have pharmacologically-active 
agents covalently bonded to the poly(alkylene glycol) mol 
ecules or entrained within the hydrogel. Living cells may also 
be entrained within the hydrogels. 
SUMMARY OF THE INVENTION 
The present invention discloses a non-toxic anti-adhesion 













biodegradable, biocompatible polysaccharides formed by 
constructing a unique interpenetrating, crosslinked network 
with a unique porosity. The invention further describes a 
method for preparing the same. 
In one embodiment the instant invention provides a method 
of making a porous anti-adhesion hydrogel comprising the 
steps of: (i) preparing an aqueous mixture of one or more 
uncrosslinked polymers and a crystallizable molecule, (ii) 
casting the aqueous mixture onto a vessel, a slide, a plate, 
tissue-culture dish or combinations and modifications thereof 
to form a cast mixture, (iii) drying the cast mixture to forman 
amorphous hydrogel film, (iv) seeding the cast mixture with a 
seed crystal of the crystallizable molecule, (v) growing the 
crystallizable molecule into a crystal structure within the 
uncrosslinked polymer, (vi) exposing the cast mixture to 
ultraviolet light, wherein the exposure results in a gelling or a 
crosslinking of the polymer, (vii) crosslinking the 
uncrosslinked polymer around the crystal structure by an 
addition of one or more crosslinking agents under conditions 
in which the crystal structure within the crosslinked polymer 
is maintained, (viii) removing the one or more crystals of the 
crystallizable polymers by rinsing with water to form the 
porous hydrogel and (ix) removing water from the porous 
hydrogel by controlled desiccation under pressure. In one 
aspect of the method comprises the optional step of Surface 
coating, modifying a surface or combinations thereof by 
soaking the dessicated hydrogel in an aqueous Solution com 
prising the uncrosslinked polymer and one or more agents or 
chemicals to facilitate formation of one or more bonds. In 
another aspect the one or more bonds comprise ester bonds, 
amide bonds, carboxylate bonds, carbonyl bonds, ether 
bonds, imide bonds, and combinations and modifications 
thereof. 
In yet another aspect of the method described hereinabove 
the polymer comprises nucleic acids, amino acids, saccha 
rides, lipids and combinations thereof, in monomeric, 
dimeric, trimeric, oligomeric, multimeric, or polymeric 
forms. In another aspect the polymer is selected from the 
group consisting of collagen, chitosan, gelatin, pectins, algi 
nate, hyaluronic acid, heparin and mixtures thereof. In a spe 
cific aspect the polymer comprises a non-synthetic biopoly 
mer that is biodegradable, biocompatible and hydrophilic. In 
another aspect the polymer is gelled by a chemical crosslink, 
a physical crosslink, or a combination; wherein said crosslink 
is induced by an UV method, a temperature method, a pH 
method, an ion, or ion-radical based method or combinations 
thereof. In one aspect in the aqueous mixture comprises algi 
nate and hyaluronic acid. In another aspect the crystallizable 
molecule comprises a small organic molecule selected from a 
salt, urea, beta cyclodextrin, glycine, and guanidine. In a 
specific aspect the crystallizable molecule comprises urea. 
In one aspect the crosslinking agent selected from group 
consisting of calcium chloride, p-AZidobenzoyl hydrazide, 
N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl 
glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suber 
imidate-2 HCl, disuccinimidyl suberate, bisSulfosuccinim 
idyl suberate, 1-ethyl-3-3-dimethylaminopropylcarbodi 
imide-HCl, isocyanate, aldehyde, glutaraldehyde, 
paraformaldehyde and derivatives thereof. In another aspect 
the method comprises the optional step of encapsulation one 
or more agents selected from drugs, growth factors, hor 
mones, proteins or combinations thereof in the one or more 
pores or the matrix of the porous hydrogel. 
In another embodiment the instant invention discloses a 
directionally networked porous anti-adhesion hydrogel made 
by a method that comprises the steps of i) preparing an 
aqueous mixture of one or more uncrosslinked polymers and 
US 9,095,558 B2 
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a crystallizable molecule, ii) casting the aqueous mixture onto 
a vessel, a slide, a plate, tissue-culture dish or combinations 
and modifications thereof to form a cast mixture, iii) drying 
the cast mixture to form an amorphous hydrogel film, iv) 
seeding the cast mixture with a seed crystal of the crystalliz 
able molecule, V) growing the crystallizable molecule into a 
crystal structure within the uncrosslinked polymer, wherein 
the crystal structure is networked, branched, and porous, vi) 
exposing the cast mixture to ultraviolet light, wherein the 
exposure results in a gelling or a crosslinking of the polymer, 
vii) crosslinking the uncrosslinked polymer around the crys 
tal structure by an addition of one or more crosslinking agents 
under conditions in which the crystal structure within the 
crosslinked polymer is maintained, viii) removing the one or 
more crystals of the crystallizable polymers by rinsing with 
water to form the porous hydrogel, and iX) removing water 
from the porous hydrogel by controlled desiccation under 
pressure. 
The method disclosed hereinabove comprises the optional 
step of Surface coating, modifying a surface or combinations 
thereof by soaking the dessicated hydrogel in an aqueous 
Solution comprising the uncrosslinked polymer and one or 
more agents or chemicals to facilitate formation of one or 
more bonds. In one aspect the one or more bonds comprise 
ester bonds, amide bonds, carboxylate bonds, carbonyl 
bonds, ether bonds, imide bonds, and combinations and 
modifications thereof. In another aspect the polymer com 
prises nucleic acids, amino acids, Saccharides, lipids and 
combinations thereof, in monomeric, dimeric, trimeric, oli 
gomeric, multimeric, or polymeric forms. In yet another 
aspect the polymer is selected from the group consisting of 
collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, 
heparin and mixtures thereof. 
In a related aspect the polymer comprises a non-synthetic 
polymer biopolymer, wherein the polymer is biodegradable, 
biocompatible and hydrophilic. In the method as described 
above the polymer is gelled by a chemical crosslink, a physi 
cal crosslink, or a combination; wherein said crosslink is 
induced by an UV method, a temperature method, a pH 
method, an ion, or ion-radical based method or combinations 
thereof. In one aspect the aqueous mixture comprises alginate 
and hyaluronic acid. In another aspect the crystallizable mol 
ecule comprises a small organic molecule selected from a 
salt, urea, beta cyclodextrin, glycine, and guanidine. In a 
specific aspect the crystallizable molecule comprises urea. In 
another aspect the crosslinking agent selected from group 
consisting of calcium chloride, p-AZidobenzoyl hydrazide, 
N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl 
glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suber 
imidate-2 HCl, disuccinimidyl suberate, bissulfosuccinim 
idyl suberate, 1-ethyl-3-3-dimethylaminopropylcarbodi 
imide-HCl, isocyanate, aldehyde, glutaraldehyde, 
paraformaldehyde and derivatives thereof. In another aspect 
the method comprises the optional step of encapsulating one 
or more agents selected from drugs, growth factors, hor 
mones, proteins or combinations thereof in the one or more 
pores or the matrix of the porous hydrogel. In yet another 
aspect the hydrogel prevents tissue adhesion following Sur 
gery, promotes wound healing, delivers drug or growth fac 
tors to the support healing, inhibits or prevents infiltration of 
blood, blood protein, fibroblasts, and inflammatory responses 
in the Surgical site and is non-cytotoxic. 
In yet another embodiment the present invention relates to 
a method of preventing tissue adhesion during or post-Surgery 
in a patient comprising the steps of identifying the patient in 
need of the prevention of tissue adhesion during or post 













adhesion composition, wherein the composition comprises a 
non-cytotoxic, a non-immunogenic porous hydrogel, a film, a 
barrier or combinations and modifications thereof, prior to, 
during or after the Surgery, wherein the composition is made 
by a method comprising the steps of: a) preparing an aqueous 
mixture of one or more uncrosslinked polymers and a crys 
tallizable molecule, b) casting the aqueous mixture onto a 
vessel, a slide, a plate, tissue-culture dish or combinations and 
modifications thereof to form a cast mixture, c) drying the 
cast mixture to form an amorphous hydrogel film, d) seeding 
the cast mixture with a seed crystal of the crystallizable mol 
ecule, e) growing the crystallizable molecule into a crystal 
structure within the uncrosslinked polymer, f) exposing the 
cast mixture to ultraviolet light, wherein the exposure results 
in a gelling or a crosslinking of the polymer, g) crosslinking 
the uncrosslinked polymer around the crystal structure by an 
addition of one or more crosslinking agents under conditions 
in which the crystal structure within the crosslinked polymer 
is maintained, h) removing the one or more crystals of the 
crystallizable polymers by rinsing with water to form the 
porous hydrogel, and i) removing water from the porous 
hydrogel by controlled desiccation under pressure. 
In one aspect the method of making the porous hydrogel 
comprises the optional steps of Surface coating, modifying a 
Surface or combinations thereof by soaking the dessicated 
hydrogel in an aqueous solution comprising the 
uncrosslinked polymer and one or more agents or chemicals 
to facilitate formation of one or more bonds and encapsulat 
ing one or more agents selected from drugs, growth factors, 
hormones, proteins or combinations thereof in the one or 
more pores or the matrix of the porous hydrogel, wherein the 
hydrogel provides a tunable or a controlled release of the one 
or more agents. In a specific aspect of the method the one or 
more agents comprise ibuprofen or tranexamic acid. In one 
aspect the composition the promotes wound healing, delivers 
drug or growth factors to the Support healing, inhibits or 
prevents infiltration of blood, blood protein, fibroblasts, and 
inflammatory responses in the Surgical site. In another aspect 
the polymer is a non-synthetic biodegradable, biocompatible 
and hydrophilic biopolymer. In a specific aspect the aqueous 
mixture comprises alginate and hyaluronic acid. In another 
aspect the crystallizable molecule comprises a small organic 
molecule selected from a salt, urea, beta cyclodextrin, gly 
cine, and guanidine. In another aspect the crystallizable mol 
ecule comprises urea. 
The present invention further discloses a composition for 
preventing tissue adhesion during or post-Surgery in a patient 
comprising an injectable solution of an anti-adhesion com 
position, wherein the composition comprises a non-cyto 
toxic, a non-immunogenic porous hydrogel, a film, a barrier 
or combinations and modifications thereof. The composition 
of the present invention is made by a method comprising the 
steps of i) preparing an aqueous mixture of one or more 
uncrosslinked polymers and a crystallizable molecule, ii) 
casting the aqueous mixture onto a vessel, a slide, a plate, 
tissue-culture dish or combinations and modifications thereof 
to form a cast mixture, iii) drying the cast mixture to forman 
amorphous hydrogel film, iv) seeding the cast mixture with a 
seed crystal of the crystallizable molecule, V) growing the 
crystallizable molecule into a crystal structure within the 
uncrosslinked polymer, vi) exposing the cast mixture to ultra 
violet light, wherein the exposure results in a gelling or a 
crosslinking of the polymer, vii) crosslinking the 
uncrosslinked polymer around the crystal structure by an 
addition of one or more crosslinking agents under conditions 
in which the crystal structure within the crosslinked polymer 
is maintained, viii) removing the one or more crystals of the 
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crystallizable polymers by rinsing with water to form the 
porous hydrogel, and iX) removing water from the porous 
hydrogel by controlled desiccation under pressure. In one 
aspect the composition is administered prior to, during or 
after the Surgery 
The present invention in one embodiment provides a 
method of making a directionally networked porous anti 
adhesion hydrogel comprising the steps of: (i) preparing an 
aqueous mixture comprising hyaluronic acid, alginic acid, 
and urea, (ii) casting the aqueous mixture onto a vessel, a 
slide, a plate, tissue-culture dish or combinations and modi 
fications thereof to form a cast mixture, (iii) drying the cast 
mixture to forman amorphous hydrogel film, (iv) seeding the 
cast mixture with one or more urea crystals, (v) growing the 
urea into a crystal structure within the uncrosslinked alginate, 
(vi) exposing the cast mixture to ultraviolet light, wherein the 
exposure results in a gelling or a crosslinking of the alginate, 
(vii) removing the one or more urea crystals by rinsing with 
water to form the porous hydrogel, and (viii) removing water 
from the porous hydrogel by controlled desiccation under 
pressure. 
The method described hereinabove comprises the optional 
steps of Surface modifying the hydrogel with hyaluronic acid 
by soaking the dessicated hydrogel in an aqueous solution of 
the hyaluronic acid in a presence of EDC/NHS and crosslink 
ing the uncrosslinked alginate around the urea crystal struc 
ture by an addition of calcium chloride under conditions in 
which the urea crystal structure within the crosslinked algi 
nate is maintained. In one aspect the method comprises the 
optional step of encapsulating one or more agents selected 
from drugs, growth factors, hormones, proteins or combina 
tions thereof in the one or more pores or the matrix of the 
porous hydrogel. In another aspect the hydrogel prevents 
tissue adhesion following Surgery, promotes wound healing, 
delivers drug or growth factors to the Support healing, inhibits 
or prevents infiltration of blood, blood protein, fibroblasts, 
and inflammatory responses in the Surgical site. 
Another embodiment of the instant invention relates to a 
method for making a bilayer biofunctionalized HA-based 
film comprising the steps of providing a first layer and a 
second layer, wherein the first layer and the second layer are 
made by a method comprising the steps of: (i) preparing an 
aqueous mixture comprising hyaluronic acid, alginic acid, 
and urea, (ii) casting the aqueous mixture onto a vessel, a 
slide, a plate, tissue-culture dish or combinations and modi 
fications thereof to form a cast mixture, (iii) drying the cast 
mixture to forman amorphous hydrogel film, (iv) seeding the 
cast mixture with one or more urea crystals, (v) growing the 
urea into a crystal structure within the uncrosslinked alginate, 
(vi) exposing the cast mixture to ultraviolet light, wherein the 
exposure results in a gelling or a crosslinking of the alginate, 
(vii) removing the one or more urea crystals by rinsing with 
water to form the porous hydrogel, and (viii) removing water 
from the porous hydrogel by controlled desiccation under 
pressure and fusing the first layer and the second layer to form 
the bilayer biofunctionalized HA-based film. In one aspect 
the first layer is a directionally networked porous anti-adhe 
sion hydrogel. In another aspect the second layer is a direc 
tionally networked porous hydrogel, wherein the second 
layer promotes cell adhesion or cell infiltration. In yet another 
aspect the method comprises the optional step of covalently 
immobilizing one or more peptides, proteins, growth hor 
mones or growth factors on the second layer. In another aspect 
the peptide is an Arginine-Glycine-Aspartic Acid (RGD) pep 
tide. In another aspect the bilayer biofunctionalized 
HA-based film is used as a nerve wrap, a dural replacement, 













ing, chronic wound repair, and patch cardiac or pulmonary 
tissues to facilitate tissue repair. 
In yet another embodiment the present invention discloses 
a composition for a nerve wrap, a dural replacement, a skin 
graft, for promoting bone in-growth in fracture dressing, 
chronic wound repair, patch cardiac or pulmonary tissues to 
facilitate tissue repair or combinations thereof comprising a 
bilayer biofunctionalized HA-based film, wherein the film is 
made by a method comprising the steps of providing a first 
layer and a second layer, wherein the first layer and the second 
layer are made by a method comprising the steps of preparing 
an aqueous mixture comprising hyaluronic acid, alginic acid, 
and urea, casting the aqueous mixture onto a vessel, a slide, a 
plate, tissue-culture dish or combinations and modifications 
thereofto form a cast mixture, drying the cast mixture to form 
an amorphous hydrogel film, seeding the cast mixture with 
one or more urea crystals, growing the urea into a crystal 
structure within the uncrosslinked alginate, exposing the cast 
mixture to ultraviolet light, wherein the exposure results in a 
gelling or a crosslinking of the alginate, removing the one or 
more urea crystals by rinsing with water to form the porous 
hydrogel, and removing water from the porous hydrogel by 
controlled desiccation under pressure and fusing the first 
layer and the second layer to form the bilayer biofunctional 
ized HA-based film. In one aspect the composition is admin 
istered by an injection, inserted or placed during, after, or 
prior to a Surgical procedure or is applied directly to an 
affected area. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures and in which: 
FIG. 1 is a schematic showing the techniques for fabricat 
ing the crystal-templated biopolymer hydrogels of the present 
invention; 
FIGS. 2A-2D show the surface modification of templated 
alginate films: FIG. 2A fluorescent biotinylated HA 
crosslinked to surface labeled with FITC/Neutravadin. When 
not crosslinked, biotinylated HA washed away (4x), FIG. 2B 
is a glass slide for FIG. 2A, FIG. 2C is a SEM of the surface 
modified film cross-sectional Surface indicating pores filled, 
scale bar 2 um, and FIG. 2D is a SEM of a templated film, no 
Surface modification, cross-sectional Surface indicating 
unfilled porous, Scale bar 1 um; 
FIGS. 3A-3C show Alginate/HA film patterned with an 
urea crystallization pattern: FIG. 3A pulling in tension, FIG. 
3B crumpling and Squeezing, and FIG. 3C returning to origi 
nal geometry with no tearing or compromise of integrity; 
FIGS. 4A and 4B show the ASTM D638 tensile testing of: 
FIG. 4A urea patterned alginate/HA film and FIG. 4B algi 
nate/HA film with no patterning: 
FIGS. 5A and 5B are examples of alginate/HA urea-tem 
plated films: FIG.5A linear patterning with 4% urea, 5" by 5" 
film, and FIG. 5B radial patterning with 6% urea, 3" by 3" 
film; 
FIG. 6 is a plot showing the ASTM D638 tensile testing of 
alginate films with increased concentration of urea crystalli 
Zation; 
FIG. 7 is a plot showing the ASTM D638 tensile testing of 
alginate films with increased concentration of HA; 
FIGS. 8A and 8B are plots showing the results of the wet 
sample degradation studies that were conducted at 37°C. in: 
FIG.8A PBS or FIG.8B 50 IU/mL of hyase. Dashed lines are 
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representative of an estimated degradation since Small bits 
can be seen visually for the duration of the study; and 
FIGS. 9A-9E show human dermal fibroblast cells (P=3) 
were cultured on: FIG. 9A a PLL substrate, FIG. 9B on 
alginate film, FIG.9C on alginate/modified HA film or FIG. 
9Dalginate/modified HA film with HA surface modification, 
FIG. 9E is a plot of the % cell adhesion on the different 
Substrates described in FIGS. 9A to 9D. 
DETAILED DESCRIPTION OF THE INVENTION 
While the making and using of various embodiments of the 
present invention are discussed in detail below, it should be 
appreciated that the present invention provides many appli 
cable inventive concepts that can be embodied in a wide 
variety of specific contexts. The specific embodiments dis 
cussed herein are merely illustrative of specific ways to make 
and use the invention and do not delimit the scope of the 
invention. 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
The instant invention describes a non-toxic anti-adhesion 
hydrogel barrier, particularly a barrier composed of non 
synthetic, hydrophilic, biodegradable, biocompatible 
polysaccharides formed by constructing a unique interpen 
etrating, crosslinked network with a unique porosity, and also 
a method for preparing the same. The hydrogel barrier 
described herein solves the problems of a film, bulk sponge or 
nonwoven type anti-adhesion system, including adhesion to 
tissue or organs, physical strength, in vivo reposition flexibil 
ity, ease of handling (i.e., bending, folding, cutting, rolling, 
manipulating), and appropriate degradation timing. 
The highly hydrophilic, non-synthetic nature of the barrier 
of the present invention selectively inhibits fibroblast infiltra 
tion into a Surgical microenvironment and because of its local 
anti-adhesive properties the barrier does not inhibit wound 
healing. The barrier of the present invention does not tear, 
break or stick to itself when folded or rolled and can be easily 
handled when using Surgical instruments lending its use in a 
variety of operations. 
The unique features of the present invention are: (i) the 
barrier is comprised of tunable biopolymers for controllable 
mechanical robustness and degradation, (ii) barrier effec 
tively reduces unwanted adhesions using non-synthetic com 
ponents, and (iii) barrier has unique, controlled hierarchical 
porosity that can be backfilled with a variety of materials that 
may also be charged with Small molecules (drugs, growth 
factors) to further inhibit unwanted response or to support 
healthy wound healing. No other technology has this combi 
nation of features. 
The unique benefits provided by the barriers described 
herein are (i) improved handling characteristics, for example 
the barrier is easily folded, cut, sutured, manipulated in bio 
logically relevant conditions, (ii) persistence in desired area 
throughout healing duration, (iii) improved in vivo reposi 
tioning flexibility, and (iv) unique porous structure that exhib 














No other methods in literature are similar to the technique 
presented herein. Current anti-adhesion technologies are 
described herein below 
U.S. Pat. No. 6,599,526 discloses a pericardial anti-adhe 
sion patch comprising a collagenous material and a non 
living cellular component for preventing adhesion during 
surgery. U.S. Pat. No. 6,566,345 discloses anti-adhesion 
compositions in the form of a fluid, gel or foam made of 
intermacromolecular complexes of polysaccharides Such as 
carboxyl-containing polysaccharides, polyethers, polyacids, 
polyalkylene oxides, etc., and synthetic polymers. Korean 
Patent Publication No. 2003-0055102 discloses an anti-adhe 
sion barrier for preventing inflammation and healing wounds 
comprising carboxymethylcellulose (CMC) and gellan gum. 
But, the anti-adhesion barriers in the form of a gel, fluid, 
foam, etc., are not accurately fixed at the wound site; they 
move downward because of gravity and, thus, are less effec 
tive in healing wounds and reducing adhesion. 
European Patent No. 092.733 discloses anti-adhesion bar 
riers in the form of a membrane, gel, fiber, nonwoven, sponge, 
etc. prepared from crosslinking of carboxymethylcellulose 
(CMC) and polyethylene oxide (PEO). However, carboxym 
ethylcellulose is less biocompatible than bio-originated mate 
rials. Since polyethylene glycol or other synthetic polymers 
are not biodegradable, only materials having a small molecu 
lar weight that are capable of being metabolized can be used. 
However, since materials having a small molecular weight are 
absorbed quickly, the role of the anti-adhesion barrier cannot 
be sustained sufficiently. 
U.S. Pat. No. 6,133,325 discloses membrane type anti 
adhesion compositions made of intermacromolecular com 
plexes of polysaccharides and polyethers. Korean Patent Pub 
lication No. 2002-0027747 discloses that a water-soluble 
polymer gel prepared from alternating copolymerization of a 
block copolymer of p-dioxanone and L-lactide with polyeth 
ylene glycol (PEG) can be utilized as an anti-adhesion barrier, 
drug carrier, tissue adhesive, alveolar membrane, etc. But, 
this gel type anti-adhesion barrier is also problematic inaccu 
rately fixing at wound sites as the abdominal internal organs 
or tissues are constantly moving. U.S. Pat. No. 6,630,167 
discloses an anti-adhesion barrier prepared from crosslinked 
hyaluronic acid. Since hyaluronic acid is a polysaccharide 
found in animal and human tissues, it has Superior biocom 
patibility. However, in an unmodified form, hyaluronic acid is 
degraded quickly, with a half life of only 1 to 3 days. This 
method in particular claims a crosslinking agent concentra 
tion of 10 to 80%, by weight, which is significantly greater 
than the 1% used in the presented technology. Crosslinking 
agents can be toxic at high concentrations and removing large 
concentrations of crosslinking agents can be difficult. 
U.S. Pat. No. 6,693,089 discloses a method of reducing 
adhesions using an alginate Solution and Korean Patent Pub 
lication No. 2002-0032351 discloses a semi-IPN (semi-inter 
penetrating network) type anti-adhesion barrier using water 
soluble alginic acid and CMC, in which alginates are 
selectively bound to calcium ions. However, these patents 
include ionically crosslinked alginate by calcium, which, 
when degraded quickly, releases a bulk charge of calcium 
ions into the Surrounding tissues, further aggravating injured 
tissues. There is also the problem of non bio-material uses. 
There are publications regarding the treatment of cellulose 
acetate with siloxane. But, since celluloses are sensitive to 
pH, there is a difficulty in processing them. Also, although 
they are natural polymers, celluloses are not a constituent of 
the human body and are known to have the potential to cause 
a foreign body reaction. Furthermore, there remains the task 
US 9,095,558 B2 
9 
of modifying their structure, e.g., through oxidation, so that 
they can be hydrolyzed inside the body. 
Anti-adhesion barriers that are currently on the market are 
in the form of a film, Sponge, fabric, gel, Solution, etc. In 
general, the film or sponge type is easier to fixata specific site 
than the solution or gel type. InterceedTM from Johnson & 
Johnson is the first commercialized anti-adhesion barrier. It is 
a fabric type product made of ORC and adheres tightly to 
highly irregular organs or tissues. But, as mentioned earlier, 
ORC is a non-bio-oriented material and has poor biocompat 
ibility. Also, because of a very large pore size, cells or blood 
proteins may easily penetrate the barrier, and the anti-adhe 
sion barrier is deformed by external force during handling. 
Seprafilm is a film type anti-adhesion barrier made of HA and 
CMC by Genzyme Biosurgery. Seprafilm tends to roll when 
in contact with water and to be brittle when dry. Thus, wet 
hands have to be avoided and moisture should be minimized 
at the surgical site, which can be very difficult. 
HYDROSORB SHIELDR) from MacroPore Biosurgery 
Inc., which is used for adhesion control in certain spinal 
applications, or SURGI-WRAPTM from Mast Biosurgery, 
USA which is used after open Surgery, are transparent film 
type anti-adhesion barriers made of poly(L-lactide-co-D.L- 
lactide) (PLA, 70:30), a biodegradable polymer. With a long 
biodegradation period of at least 4 weeks and Superior 
mechanical strength, they are known as easy-to-handle prod 
ucts. Films made of PLA or poly(glycolic acid) (PGA) are 
easy to roll to one side, but they do not adhere well to the 
three-dimensionally, highly irregular Surfaces of organs or 
tissues. Also, since these materials are hydrophobic, they do 
notabsorb moisture well, and, therefore, do not adhere well to 
the wet surface of organs or tissues. Also, when hydrolyzed in 
the body, these materials release acidic degradation products, 
which may cause further inflammation and adhesion. 
DuraGen(R) and DuraGen Plus(R from Integra LifeSciences is 
a sponge type anti-adhesion barrier made of collagen from an 
animal source, which has been developed for Surgery and 
neuroSurgery. Since the collagen sponge absorbs moisture, it 
readily adheres to the surface of organs. However, these bar 
riers have relatively weak physical strength and, because of 
excessive moisture absorption, tends to be too heavy to 
handle or transport to another site. 
In general, an anti-adhesion barrier has to satisfy the fol 
lowing requirements: i) infiltration or attachment of cells or 
blood should be avoided through precise control of pore size 
or use of materials non-adherent to blood or cells, ii) the 
anti-adhesion barrier should be able to be attached at the 
desired site for a specified period of time, iii) a foreign body 
reaction should be minimized to reduce inflammation, which 
is the cause of adhesion, iv) the biodegradation period should 
be able to be controlled, so that the barrier capacity can be 
Sustained for a requisite period of time, V) the anti-adhesion 
barrier should be flexible and have superior mechanical prop 
erties, including tensile strength and wet strength, for ease of 
handling during Surgery, and vi) there should be no deforma 
tion for a necessary period of time, because the wound should 
be covered exactly. 
Post-Surgical adhesions tether tissues that should remain 
separate. Adhesions result from impaired autologous natural 
immune response. Surgical adhesions continue to plague the 
recovery period, with current technologies falling short of 
adhesion prevention. Incidence of adhesions following Sur 
gery is 80% (Yeo, 2007) resulting in chronic pain, limited 
motion, organ dysfunction, and even death (Cui et al., 2009). 
The healthcare costs associated with this are over S3.45 bil 
lion, annually (Wiseman, et al., 2010). Current approaches 














(Holmdahl et al., 1997) (for e.g., powder free gloves, laparo 
scopic procedures, and reduction of desiccation), biocompat 
ible barrier devices (for e.g., polymer Solutions, in situ 
crosslinkable hydrogels, pre-formed membranes), and phar 
macotherapy agents like steroidal anti-inflammatory drugs 
(Dexamethasone; progesterone; hydrocortisone; pred 
nisone), non-steroidal anti-inflammatory drugs (Ibuprofen; 
flurbiprofen; indomethacin; tolmetin: nimesulide), inhibitors 
of proinflammatory cytokines (Antibodies to transforming 
growth factor (TGF)-b1), antihistamine (Diphenhydramine: 
promethazine), free radical scavengers (Melatonin; Vitamin 
E.; Superoxide dismutase), Anticoagulants (heparin), pro 
teolytic agents (tissue-type plasminogen activator, streptoki 
nase; urokinase; pepsin; trypsin; Neurokinin 1 receptor 
antagonist), and antiproliferative agents (mitomycin). 
The most effective anti-adhesion barrier on the market 
reduces adhesion formation by only 50%. Many products are 
based on synthetic materials because of Superior handling 
capabilities and low manufacturing costs. However, these 
synthetic materials are rendered ineffective in the presence of 
blood or blood proteins. The invention presented herein 
addresses the problems listed above and provides an effective 
method of blocking the infiltration of unwanted inflammatory 
response while maintaining robust mechanical properties for 
Surgical handling. Because the present invention is con 
structed of natural materials, the risk of further aggravation is 
minimized, while blood and blood proteins will not adhere. 
Barriers on the market made from natural materials also 
degrade too quickly, allowing for adhesion formation. The 
present technology has a tunable degradation rate so that the 
barrier persists during the healing process. 
Current products on the market that are most effective have 
poor handling properties. They are brittle when dry and are 
rendered inapplicable when wet. In an OR environment, a 
Suitable solution would be able to maintain mechanical integ 
rity when wet. The present invention offers superior handling 
properties when wet including in Vivo repositioning capabili 
ties and suturability. 
The present invention describes the development of com 
posite, dual-functioning materials to be placed at the interface 
between healing tissues and the Surrounding tissues. The 
invention improves upon anti-adhesive biomaterial barriers, 
to aid in wound healing, and to modulate the inflammatory 
response. The present inventors have develop and character 
ize anti-adhesive HA-based material (biocompatible, non 
immunogenic, non cell-adhesive, inhibits protein absorption, 
mechanically stable, cost effective, clinically sized, and 
appropriate degradation rate). In addition the present inven 
tors have developed a bilayer biofunctionalized HA-based 
film that is biocompatible, bioabsorbable, non-immunogenic, 
dual functioning, regenerative, anti-adhesive, mechanically 
stable, cost effective, and clinically sized. Finally, they 
develop an injectable solution version of anti-adhesive film 
that is biocompatible, effective at reducing adhesions, encap 
Sulates ibuprofen or tranexamic acid and has tunable release 
rates. 
Hydrogels are generally polymer chain networks that are 
water-insoluble, but that absorb water. Often described as 
being “superabsorbent,” hydrogels are able to retain up to 
99% water and can be made from natural or synthetic poly 
mers. Often, hydrogels will have a high degree of flexibility 
due to their high water content. Common uses for hydrogels 
include: Sustained drug release, as Scaffolds (e.g., in tissue 
engineering), as a thickening agent, as a biocompatible poly 
mer, in biosensors and electrodes and for tissue replacement 
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applications. Natural hydrogels may be made from agarose, 
methylcellulose, hyaluronic acid (HA), and other naturally 
derived polymers. 
HA is a linear polysaccharide with repeating disaccharide 
units composed of sodium D-glucuronate and N-acetyl-D- 
glucosamine. This naturally occurring glycosaminoglycan is 
a component of skin, synovial fluid, and Subcutaneous and 
interstitial tissues. HA is metabolically eliminated from the 
body, and plays a role in protecting and lubricating cells and 
maintaining the structural integrity of tissues. Anionic car 
boxylic groups immobilize water molecules giving HA its 
viscoelastic and anti cell-adhesive properties. HA has been 
used in a variety of material designs for the prevention of 
postSurgical tissue adhesion. HA has been used as a dilute 
solution, a crosslinked hydrogel, or combined with CMC into 
sheets. HA is biocompatible, bioabsorbable/non-immuno 
genic (non-animal), very non-cell adhesive, polyanionic, 
hydrophilic, antifibrotic (1% HMW HA, Massie, 2005), pro 
angiogenic and has been shown to reduce adhesion formation 
in animals and humans (Zawaneh, 2008; Diamond, 2006; 
Wiseman, 2010; Rajab, 2010). HA is clinically used to reduce 
adhesions: SeprafilmR), most effective and widely used anti 
adhesion barrier on the market. 
Alginic acid is biocompatible, bioabsorbable/non-immu 
nogenic (non-animal) (Skjak-Braek, 1992), very non-cell 
adhesive, polyanionic, hydrophilic, cost effective, abundant 
(brown seaweed), mechanically viable for handling/Suturing 
in ionically crosslinked form, and is shown to be significantly 
effective at adhesion prevention in animal models (Namba, 
2006; Cho, 2010a; Cho, 2010b). 
Attributes of alginate that statistically alter mechanical 
properties: (i) grade (Purification), (ii) gulcuronate to man 
nuronate ratio (High Mratio is pond-grown, primarily leaves, 
High G is deep sea harvested, primarily stems), and (iii) 
molecular weight/viscosity. However, highly purified algi 
nate is very expensive ~S100/g, lower grade (inexpensive) 
alginates are not tested for molecular weight or G:M ratio, 
and purification processes are not standardized. 
Crystal templated hydrogels of alginate and HA were cre 
ated by casting a droplet of Solution containing a photo 
crosslinkable derivative of HA, a photocrosslinkable deriva 
tive of alginate with photoinitiator (PI) and urea (FIG. 1). The 
Solvent is evaporated and a urea seed crystal is touched to the 
droplet to nucleate urea crystallization. After crystallization 
the alginate and HA are photocrosslinked by UV exposure. 
Alginate may be further crosslinked ionically and rinsed with 
water to remove the urea leaving behind an alginate/HA 
hydrogel templated with the pattern of the urea crystals. The 
hydrogel may then be dehydrated for further surface modifi 
cation using crosslinking agents (such as water soluble car 
bodiimides in ethanol/deionized water mixtures). 
The method for preparing the alginate/HA films as 
described in the present invention includes five steps: film 
casting, solvent evaporation, crystal growth, crosslinking, 
and rinsing. In the first step a Syringe filter introduces a 
Solution comprising alginate/GMHA/urea on a plate. The 
solution is then cast as a film at 25° C. at 70% relative 
humidity. Solvent evaporation is required to achieve the 
Super-saturation conditions necessary for crystallization. 
Evaporation also greatly increases the biopolymer concentra 
tion and Solution viscosity. The combination of high viscosity 
and hydrogen bonding Suppresses spontaneous urea crystal 
lization and facilitates Super-saturation. Urea seed crystals 
are deposited on the tips of a fine pair of tweezers and is added 
to nucleate crystallization followed by exposure to UVA (500 
mW/cm) for 15 secs. Crystal growth began immediately and 













center to the edge of the film. Within seconds the entire 
volume of the hydrogel films were filled with urea crystals. 
These crystals comprised the urea crystal template. The films 
may optionally be crosslinked by an addition of one or more 
cross linking agents (for example an ionic crosslinking solu 
tion like CaCl is added to the film to crosslink the alginate). 
The urea crystals are then rinsed out with double distilled 
water. The film formed thus is subjected to controlled desic 
cation under force to remove water at 50% relative humidity. 
The dehydrated film may be subjected to further surface 
modification by creating one or more ester or less hydrolys 
able bonds by a variety of techniques (got e.g., soaking in a 
HA solution using water soluble carbodiimide for ester 
bonds). 
Alginate films alone degraded too quickly in chelating 
environment. Calcium ions chelated by multiple salts and can 
degrade within a few hours. (Islam, 2010). Adding GMHA 
decreases degradation, but without compromising the 
mechanical strength provided by alginate. Alginate film, 
alone, is too brittle and breaks with little manipulation. Add 
ing urea introduces micron-sized pores which provide flex 
ibility because spaces accept forces first. 
FIGS. 2A-2D show the surface modification of templated 
alginate films. FIG. 2A shows fluorescent biotinylated HA 
crosslinked to surface labeled with FITC/Neutravadin. When 
not crosslinked, biotinylated HA washed away (4x). FIG. 2B 
is a glass slide for FIG. 2A. FIG. 2C are is a SEM of the 
Surface-modified film cross-sectional Surface indicating 
pores filled, scale bar2 um and of a templated film, no Surface 
modification, cross-sectional Surface indicating unfilled 
porous, scale bar 1 um, respectively. 
FIGS. 3A-3C are images showing the integrity of the Algi 
nate/HA film patterned with an urea crystallization pattern, 
pulling in tension (FIG. 3A), crumpling and Squeezing (FIG. 
3B), and returning to original geometry with no tearing or 
compromise of integrity (FIG. 3C). 
The ASTM D638 tensile testing of urea patterned alginate/ 
HA film and alginate/HA film with no patterning is shown in 
FIGS. 4A and 4B. The patterned film recoils in response to 
plastic deformation before failure. The non-patterned film 
breaks with a brittle fracture. Examples of alginate/HA urea 
templated films are shown in FIGS. 5A and 5B, linear pat 
terning with 4% urea, 5" by 5" film (5A), and radial patterning 
with 6% urea, 3" by 3" film (5B). 
FIG. 6 is a plot showing the ASTM D638 tensile testing of 
alginate films with increased concentration of urea crystalli 
Zation. The trend indicates increased plasticity with increased 
crystallization patterning. FIG. 7 is a plot showing the ASTM 
D638 tensile testing of alginate films with increased concen 
tration of HA. The trend indicates decreased tensile strength 
with increased HA, until a critical point, where the concen 
tration of HA improves the tensile strength by providing 
crosslinked strength. 
Characterization of synthesized Alginate/HA films: FIGS. 
8A and 8B are plots showing the results of the wet sample 
degradation studies of an Alginate/HA film of the present 
invention conducted at 37°C. in PBS or 50 IU/mL of hyase, 
respectively. Briefly, the method involves determining a pre 
test weight of the Alginate/HA film (or films) (W), after that 
the film is placed in PBS or the hyase at 37° C. and are 
removed at pre-defined time points and weighed (W). The 
procedure is repeated until the weight cannot be taken or the 
appropriate pre-defined end point time is reached. The deg 
radation rate is calculated using the formula given below: 
% Weight Loss=100x(W-WA/W, 
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Dashed lines are representative of an estimated degrada 
tion since small bits can be seen visually for the duration of 
the study. Alginate alone films degrade due to chelating 
agents in the buffer. 
FIG. 9 is a schematic showing the steps involved in the 
evaluation of the anti-cell adhesion properties of an alginate/ 
HA film of the present invention. A culture offibroblast cells 
is taken, half of it is retained on a TCPS dish and the other half 
is retained on an Alginate/HA film that has been placed on a 
dish. After a 24 hour waiting period, both the dishes are 
stained with calcein/ethidium to label the live or dead cells. 
The cell adhesion or non cell adhesion is validated using one 
or more commonly used cell technologies. 
To study cell adhesion properties human dermal fibroblasts 
cells (P-3) were cultured on a PLL substrate, on alginate film, 
on alginate/modified HA film or alginate/modified HA film 
with HA surface modificationalginate/HA film of the present 
invention (FIGS.9A-9D). A culture offibroblast cells is taken 
and split in half and placed separately on two TCPS dishes. 
The film/substrate to be tested is placed on top of one of the 
dishes. After a 6 hour waiting period, both the dishes are 
stained with calcein/ethidium to label the live or dead cells. 
FIG. 9E is a plot of the % cell adhesion on the different 
substrates described in FIGS. 9A to 9D. Leaching studies 
showed no cytotoxic results from film, staining at 24 hours. 
The barrier disclosed hereinabove possesses significant 
advantages over currently existing technologies: (1) the bar 
rier has improved handling characteristics, is easily folded, 
cut, Sutured, manipulated in biologically relevant conditions; 
(2) barrier persists in desired area throughout healing dura 
tion; (3) barrier has improved in vivo repositioning flexibility; 
and (4) unique porous structure that exhibits atunable release 
profile for material, Small molecules, or growth factors. 
The unique anti-adhesive membrane described herein 
above could also be an innovative Solution in the enormous 
wound care market. As a Substrate for a non-adhesive, hydro 
philic, yet absorbent wound dressing, the present invention 
can be used extensively in burn care, chronic non-healing 
wound care, and reconstructive plastic Surgery. 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method, 
kit, reagent, or composition of the invention, and vice versa. 
Furthermore, compositions of the invention can be used to 
achieve methods of the invention. 
It will be understood that particular embodiments 
described herein are shown by way of illustration and not as 
limitations of the invention. The principal features of this 
invention can be employed in various embodiments without 
departing from the scope of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
routine experimentation, numerous equivalents to the specific 
procedures described herein. Such equivalents are considered 
to be within the scope of this invention and are covered by the 
claims. 
All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those skilled 
in the art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli 
cation was specifically and individually indicated to be incor 
porated by reference. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one.” and “one or more 
than one.” The use of the term 'or' in the claims is used to 













tives only or the alternatives are mutually exclusive, although 
the disclosure supports a definition that refers to only alter 
natives and “and/or.” Throughout this application, the term 
“about is used to indicate that a value includes the inherent 
variation of error for the device, the method being employed 
to determine the value, or the variation that exists among the 
study Subjects. 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
“comprises”), “having (and any form of having, such as 
“have” and “has'), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, Such as “contains and “contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
The term “or combinations thereofas used herein refers to 
all permutations and combinations of the listed items preced 
ing the term. For example, A, B, C, or combinations thereof 
is intended to include at least one of A, B, C, AB, AC, BC, or 
ABC, and if order is important in a particular context, also 
BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing 
with this example, expressly included are combinations that 
contain repeats of one or more item or term, such as BB, 
AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and 
so forth. The skilled artisan will understand that typically 
there is no limit on the number of items or terms in any 
combination, unless otherwise apparent from the context. 
All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described interms of preferred embodiments, it will be appar 
ent to those of skill in the art that variations may be applied to 
the compositions and/or methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
All Such similar Substitutes and modifications apparent to 
those skilled in the art are deemed to be within the spirit, 
Scope and concept of the invention as defined by the appended 
claims. 
What is claimed is: 
1. An apparatus comprising: 
a dessicated, amorphous, translucent, flexible, hydrogel 
film including: 
a first film layer comprising uncrosslinked hyaluronic 
acid and alginate that is negatively charged and 
crosslinked with at least one calcium cation; and 
a second film layer comprising uncrosslinked hyaluronic 
acid and alginate that is negatively charged and 
crosslinked with at least one calcium cation; 
wherein (a) the first film layer is fused to the second film 
layer; and (b) the first film layer is anti-adhesive and 
non-attractive to cells and the second film layer is adhe 
sive to cells. 
2. The apparatus of claim 1, wherein the hyaluronic acid 
and alginate in the first layer are formed around a pore net 
work. 
3. The apparatus of claim 2, wherein the pore network is 
branched. 
4. The apparatus of claim 1, wherein the hydrogel film is 
bonded to a Surface coating via one or more bonds comprising 
ester bonds, carboxylate bonds, carbonyl bonds, ether bonds, 
imide bonds, and combinations thereof. 
5. The apparatus of claim 1 wherein the hydrogel film is 
configured to prevent tissue adhesion following Surgery. 
6. The apparatus of claim 1, wherein the hydrogel film is 
non-cytotoxic. 
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7. The apparatus of claim 1, wherein the hydrogel film 
encapsulates at least one of a drug, growth factor, hormone, 
protein, and combinations thereof. 
8. The apparatus of claim 1, wherein the hydrogel film is 
unpatterned. 5 
9. The apparatus of claim 1 comprising hyaluronic acid 
crosslinked to an outer surface of the hydrogel film. 
10. The apparatus of claim 1 comprising: 
wherein the second layer includes channels comprising at 
least one of a drug, growth factor, hormone, protein, and 10 
combinations thereof. 
11. The apparatus of claim 1 comprising at least 1% and no 
more than 33% composition hyaluronic acid. 
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